- $199.11m
- $148.27m
- $39.30m
- 47
- 16
- 22
- 18
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.26 | 6.05 | 13 | 22.5 | 39.3 |
Cost of Revenue | |||||
Gross Profit | 4.57 | 4.61 | 9.4 | 17.5 | 33 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 16.5 | 17.6 | 37.7 | 63.7 | 82.4 |
Operating Profit | -10.2 | -11.5 | -24.7 | -41.2 | -43.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -14.6 | -14 | -43 | -41.3 | -41.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.6 | -14.1 | -43.1 | -41.4 | -41.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -14.6 | -14.1 | -43.1 | -41.4 | -41.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.6 | -14.3 | -43.1 | -41.4 | -41.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.759 | -0.742 | -2.14 | -2.06 | -1.99 |